JPWO2020097403A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020097403A5 JPWO2020097403A5 JP2021525078A JP2021525078A JPWO2020097403A5 JP WO2020097403 A5 JPWO2020097403 A5 JP WO2020097403A5 JP 2021525078 A JP2021525078 A JP 2021525078A JP 2021525078 A JP2021525078 A JP 2021525078A JP WO2020097403 A5 JPWO2020097403 A5 JP WO2020097403A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- cells
- antigen
- hours
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 183
- 150000001875 compounds Chemical class 0.000 claims description 168
- 239000000427 antigen Substances 0.000 claims description 128
- 108091007172 antigens Proteins 0.000 claims description 128
- 102000038129 antigens Human genes 0.000 claims description 128
- 210000004027 cells Anatomy 0.000 claims description 89
- 108010083359 Antigen Receptors Proteins 0.000 claims description 71
- 102000006306 Antigen Receptors Human genes 0.000 claims description 71
- 102000005962 receptors Human genes 0.000 claims description 56
- 108020003175 receptors Proteins 0.000 claims description 56
- 238000002659 cell therapy Methods 0.000 claims description 55
- 230000002519 immonomodulatory Effects 0.000 claims description 48
- 102100018530 CRBN Human genes 0.000 claims description 44
- 108060001884 CRBN Proteins 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 39
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 32
- 101700005406 IKZF1 Proteins 0.000 claims description 30
- 102100008719 IKZF1 Human genes 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 230000002401 inhibitory effect Effects 0.000 claims description 27
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 102000017182 Ikaros Transcription Factor Human genes 0.000 claims description 25
- 108010013958 Ikaros Transcription Factor Proteins 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 25
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 230000000977 initiatory Effects 0.000 claims description 23
- 101700043522 IKZF3 Proteins 0.000 claims description 21
- 102100004859 IKZF3 Human genes 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 239000012472 biological sample Substances 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 16
- 239000000523 sample Substances 0.000 claims description 16
- -1 CD44v7/8 Proteins 0.000 claims description 15
- 102100007097 DCT Human genes 0.000 claims description 15
- 102100008382 FCRL5 Human genes 0.000 claims description 15
- 101700031417 FCRL5 Proteins 0.000 claims description 15
- 102100017640 SLAMF7 Human genes 0.000 claims description 15
- 101710030435 SLAMF7 Proteins 0.000 claims description 15
- 230000015556 catabolic process Effects 0.000 claims description 15
- 230000004059 degradation Effects 0.000 claims description 15
- 238000006731 degradation reaction Methods 0.000 claims description 15
- 230000002708 enhancing Effects 0.000 claims description 15
- 210000001519 tissues Anatomy 0.000 claims description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 238000010798 ubiquitination Methods 0.000 claims description 14
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 12
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 12
- 102100001891 CTAG1A Human genes 0.000 claims description 12
- 101710004449 CTAG1A Proteins 0.000 claims description 12
- 102100004400 L1CAM Human genes 0.000 claims description 12
- 210000004369 Blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 102100005826 CD19 Human genes 0.000 claims description 10
- 101700087100 CD19 Proteins 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 9
- 229960004397 Cyclophosphamide Drugs 0.000 claims description 9
- 101710004105 DCT Proteins 0.000 claims description 9
- 102100013180 KDR Human genes 0.000 claims description 9
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims description 9
- 102100009581 TPBG Human genes 0.000 claims description 9
- 101700065141 TPBG Proteins 0.000 claims description 9
- 102100007096 TYRP1 Human genes 0.000 claims description 9
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 9
- 239000002269 analeptic agent Substances 0.000 claims description 9
- 230000002354 daily Effects 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 8
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 230000004936 stimulating Effects 0.000 claims description 8
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims description 7
- 102100000189 CD22 Human genes 0.000 claims description 7
- 101700020617 CD22 Proteins 0.000 claims description 7
- 210000004698 Lymphocytes Anatomy 0.000 claims description 7
- 102100000165 MS4A1 Human genes 0.000 claims description 7
- 101710010909 MS4A1 Proteins 0.000 claims description 7
- 101710040533 TNFRSF8 Proteins 0.000 claims description 7
- 102100009538 TNFRSF8 Human genes 0.000 claims description 7
- 230000001605 fetal Effects 0.000 claims description 7
- 229960000390 fludarabine Drugs 0.000 claims description 7
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 7
- 230000001965 increased Effects 0.000 claims description 7
- 230000002035 prolonged Effects 0.000 claims description 7
- 102100001537 CA9 Human genes 0.000 claims description 6
- 102100003279 CD38 Human genes 0.000 claims description 6
- 101700044948 CD38 Proteins 0.000 claims description 6
- 102100005828 CD5 Human genes 0.000 claims description 6
- 101700066525 CD5 Proteins 0.000 claims description 6
- 102100011842 CEACAM5 Human genes 0.000 claims description 6
- 102100009368 CR2 Human genes 0.000 claims description 6
- 101700020447 CR2 Proteins 0.000 claims description 6
- 102100002013 CSPG4 Human genes 0.000 claims description 6
- 108010088013 Carbonic Anhydrase IX Proteins 0.000 claims description 6
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 6
- 206010052015 Cytokine release syndrome Diseases 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 241000701022 Cytomegalovirus Species 0.000 claims description 6
- 102100010813 EGF Human genes 0.000 claims description 6
- 101700033006 EGF Proteins 0.000 claims description 6
- 101700036477 FOLH1 Proteins 0.000 claims description 6
- 102100008453 FOLH1 Human genes 0.000 claims description 6
- 101700060135 GNMT Proteins 0.000 claims description 6
- 102100006970 GPRC5D Human genes 0.000 claims description 6
- 101710045409 GPRC5D Proteins 0.000 claims description 6
- 210000000265 Leukocytes Anatomy 0.000 claims description 6
- 102100006037 MUC1 Human genes 0.000 claims description 6
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 6
- 108010008707 Mucin-1 Proteins 0.000 claims description 6
- 102100017963 PSCA Human genes 0.000 claims description 6
- 101700038464 PSCA Proteins 0.000 claims description 6
- 102100005499 PTPRC Human genes 0.000 claims description 6
- 101700059076 PTPRC Proteins 0.000 claims description 6
- 102100010587 SDC1 Human genes 0.000 claims description 6
- 101700070405 SDC1 Proteins 0.000 claims description 6
- 102100009744 TNFRSF13B Human genes 0.000 claims description 6
- 101710030909 TNFRSF13B Proteins 0.000 claims description 6
- 101710030862 TNFRSF13C Proteins 0.000 claims description 6
- 102100009743 TNFRSF13C Human genes 0.000 claims description 6
- 101700000513 TYRP1 Proteins 0.000 claims description 6
- 108091007928 VEGF receptors Proteins 0.000 claims description 6
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 6
- 102100008060 WT1 Human genes 0.000 claims description 6
- 101700062995 WT1 Proteins 0.000 claims description 6
- 208000008383 Wilms Tumor Diseases 0.000 claims description 6
- 102100014338 ZNF654 Human genes 0.000 claims description 6
- 102000004965 antibodies Human genes 0.000 claims description 6
- 108090001123 antibodies Proteins 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 230000001351 cycling Effects 0.000 claims description 6
- 108010051081 dopachrome isomerase Proteins 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 102000006495 integrins Human genes 0.000 claims description 6
- 108010044426 integrins Proteins 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 210000003071 memory T lymphocyte Anatomy 0.000 claims description 6
- 102000003735 mesothelin Human genes 0.000 claims description 6
- 108090000015 mesothelin Proteins 0.000 claims description 6
- 231100000004 severe toxicity Toxicity 0.000 claims description 6
- 101700017647 CD33 Proteins 0.000 claims description 5
- 102100016493 CD33 Human genes 0.000 claims description 5
- 108050007237 Glypican-3 Proteins 0.000 claims description 5
- 241000571697 Icarus Species 0.000 claims description 5
- 102100002407 LRRC8A Human genes 0.000 claims description 5
- 101710030870 LRRC8A Proteins 0.000 claims description 5
- 241000673185 Aeolus Species 0.000 claims description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 4
- 101700033362 CD28 Proteins 0.000 claims description 4
- 102100019461 CD28 Human genes 0.000 claims description 4
- 206010029350 Neurotoxicity Diseases 0.000 claims description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 4
- 125000005418 aryl aryl group Chemical group 0.000 claims description 4
- 230000000779 depleting Effects 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000002887 neurotoxic Effects 0.000 claims description 4
- 231100000228 neurotoxicity Toxicity 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 230000001717 pathogenic Effects 0.000 claims description 4
- 244000052769 pathogens Species 0.000 claims description 4
- CXQCLLQQYTUUKJ-ALWAHNIESA-N (2S,4S,5R,6R)-5-acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[ Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 CXQCLLQQYTUUKJ-ALWAHNIESA-N 0.000 claims description 3
- LHWDRTXZYZBFET-YBFHIOIGSA-N (2S,4S,5R,6R)-5-acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-6-[(E,2S,3R)-2-formamido-3-hydroxyoctadec-4-enoxy]-4,5-dihyd Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC=O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O)[C@@H](CO)O1 LHWDRTXZYZBFET-YBFHIOIGSA-N 0.000 claims description 3
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 3
- 102100007326 BIRC5 Human genes 0.000 claims description 3
- 101710042656 BQ2027_MB1231C Proteins 0.000 claims description 3
- 101700047069 BTLA Proteins 0.000 claims description 3
- 102100009333 BTLA Human genes 0.000 claims description 3
- 102100005858 CCNA2 Human genes 0.000 claims description 3
- 102100014174 CD160 Human genes 0.000 claims description 3
- 101710039069 CD160 Proteins 0.000 claims description 3
- 102100000197 CD24 Human genes 0.000 claims description 3
- 108060001249 CD24 Proteins 0.000 claims description 3
- 102100019456 CD276 Human genes 0.000 claims description 3
- 101700015421 CD276 Proteins 0.000 claims description 3
- 101700078950 CD44 Proteins 0.000 claims description 3
- 102100003735 CD44 Human genes 0.000 claims description 3
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 3
- 101710030372 CLSTN1 Proteins 0.000 claims description 3
- 101710038812 CS1 Proteins 0.000 claims description 3
- 101700054183 CTLA4 Proteins 0.000 claims description 3
- 102100005310 CTLA4 Human genes 0.000 claims description 3
- 102000008646 Carbonic Anhydrase IX Human genes 0.000 claims description 3
- 102000010864 Carbonic anhydrase 9 Human genes 0.000 claims description 3
- 108010060273 Cyclin A2 Proteins 0.000 claims description 3
- 102000016736 Cyclins Human genes 0.000 claims description 3
- 108050006400 Cyclins Proteins 0.000 claims description 3
- 102100010782 EGFR Human genes 0.000 claims description 3
- 101700039191 EGFR Proteins 0.000 claims description 3
- 102100009509 ENTPD1 Human genes 0.000 claims description 3
- 101710011427 ENTPD1 Proteins 0.000 claims description 3
- 102100016692 ESR1 Human genes 0.000 claims description 3
- 102000025478 Eph receptors Human genes 0.000 claims description 3
- 108091008122 Eph receptors Proteins 0.000 claims description 3
- 101700053597 FCER2 Proteins 0.000 claims description 3
- 102100014608 FCER2 Human genes 0.000 claims description 3
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 3
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 3
- 102100016472 GP2 Human genes 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 101710004393 HAVCR2 Proteins 0.000 claims description 3
- 102100016384 HAVCR2 Human genes 0.000 claims description 3
- 208000002672 Hepatitis B Diseases 0.000 claims description 3
- 102100016020 IFNG Human genes 0.000 claims description 3
- 101700086956 IFNG Proteins 0.000 claims description 3
- 102100004549 IL13RA2 Human genes 0.000 claims description 3
- 101710034342 IL13RA2 Proteins 0.000 claims description 3
- 102100018760 IL3RA Human genes 0.000 claims description 3
- 101710021997 ITPRID2 Proteins 0.000 claims description 3
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims description 3
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 108060004270 LAG3 Proteins 0.000 claims description 3
- 102100017213 LAG3 Human genes 0.000 claims description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 3
- 102100008857 MLANA Human genes 0.000 claims description 3
- 101710012533 MLANA Proteins 0.000 claims description 3
- 102100006044 MUC16 Human genes 0.000 claims description 3
- 101700008449 MUC16 Proteins 0.000 claims description 3
- 102100015992 NCR3LG1 Human genes 0.000 claims description 3
- 101710036691 NCR3LG1 Proteins 0.000 claims description 3
- 102100011908 NRCAM Human genes 0.000 claims description 3
- 101700048788 NRCAM Proteins 0.000 claims description 3
- 101710017470 NT5C3B Proteins 0.000 claims description 3
- 102100017157 PROM1 Human genes 0.000 claims description 3
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 3
- 102100017729 ROR1 Human genes 0.000 claims description 3
- 101710036428 ROR1 Proteins 0.000 claims description 3
- 102100013504 RPL17 Human genes 0.000 claims description 3
- 108060007796 SPATA2 Proteins 0.000 claims description 3
- 101800001271 Surface protein Proteins 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- 102000003705 Syndecan-1 Human genes 0.000 claims description 3
- 108090000058 Syndecan-1 Proteins 0.000 claims description 3
- 102000019361 Syndecans Human genes 0.000 claims description 3
- 108050006774 Syndecans Proteins 0.000 claims description 3
- 102100004274 TCL1B Human genes 0.000 claims description 3
- 101700062340 TCL1B Proteins 0.000 claims description 3
- 101700052319 TIGIT Proteins 0.000 claims description 3
- 102100006047 TIGIT Human genes 0.000 claims description 3
- 101700019638 TRPC4 Proteins 0.000 claims description 3
- 210000001550 Testis Anatomy 0.000 claims description 3
- 101710009757 UROD Proteins 0.000 claims description 3
- 101710036075 VSIR Proteins 0.000 claims description 3
- 102100015314 VSIR Human genes 0.000 claims description 3
- 101700036918 XMT1 Proteins 0.000 claims description 3
- 102000034433 acetylcholine receptors Human genes 0.000 claims description 3
- 108020000715 acetylcholine receptors Proteins 0.000 claims description 3
- 101710034429 ctaG1 Proteins 0.000 claims description 3
- 108040003506 cyclic ADP-ribose hydrolase Proteins 0.000 claims description 3
- 230000001472 cytotoxic Effects 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001809 detectable Effects 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 3
- 108010038795 estrogen receptors Proteins 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 230000002757 inflammatory Effects 0.000 claims description 3
- 108010027445 interleukin-22 receptor Proteins 0.000 claims description 3
- 230000002147 killing Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002085 persistent Effects 0.000 claims description 3
- 102000003998 progesterone receptors Human genes 0.000 claims description 3
- 108090000468 progesterone receptors Proteins 0.000 claims description 3
- 230000002062 proliferating Effects 0.000 claims description 3
- 108091007921 receptor tyrosine kinases Proteins 0.000 claims description 3
- 102000027656 receptor tyrosine kinases Human genes 0.000 claims description 3
- 101710029131 rpsA Proteins 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 101710042243 trpE(G) Proteins 0.000 claims description 3
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 claims description 3
- 101710041788 ygbT Proteins 0.000 claims description 3
- 210000001124 Body Fluids Anatomy 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 102100003729 CD40LG Human genes 0.000 claims description 2
- 102100011168 EFNB2 Human genes 0.000 claims description 2
- 108010044090 Ephrin-B2 Proteins 0.000 claims description 2
- 102000003688 G-protein coupled receptors Human genes 0.000 claims description 2
- 108090000045 G-protein coupled receptors Proteins 0.000 claims description 2
- 206010025650 Malignant melanoma Diseases 0.000 claims description 2
- 101710040448 TNFRSF4 Proteins 0.000 claims description 2
- 102100013135 TNFRSF4 Human genes 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 230000000735 allogeneic Effects 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 230000001684 chronic Effects 0.000 claims description 2
- 230000005713 exacerbation Effects 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 150000003840 hydrochlorides Chemical class 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000002459 sustained Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 48
- 150000002367 halogens Chemical group 0.000 claims 3
- 102100007996 GPC3 Human genes 0.000 claims 2
- 101700058902 RORA Proteins 0.000 claims 2
- 102100010912 EPCAM Human genes 0.000 claims 1
- 108060002563 EPCAM Proteins 0.000 claims 1
- 101710037116 GAPC3 Proteins 0.000 claims 1
- 101700044749 GPC3 Proteins 0.000 claims 1
- 229910017711 NHRa Inorganic materials 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 1
- 230000002045 lasting Effects 0.000 claims 1
- 210000004901 leucine-rich repeat Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 20
- 230000011664 signaling Effects 0.000 description 20
- 239000000556 agonist Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 210000003719 B-Lymphocytes Anatomy 0.000 description 5
- 230000001086 cytosolic Effects 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 102000018109 Glypican-3 Human genes 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 3
- 102100000690 CHL1 Human genes 0.000 description 3
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 3
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 3
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 3
- 201000003444 follicular lymphoma Diseases 0.000 description 3
- 230000002250 progressing Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000004235 Neutropenia Diseases 0.000 description 2
- 206010025310 Other lymphomas Diseases 0.000 description 2
- 102100006759 PRAME Human genes 0.000 description 2
- 108060006580 PRAME Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 2
- 108091008153 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 101800000385 Transmembrane protein Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 201000009251 multiple myeloma Diseases 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- ZXWQZGROTQMXME-KMPXOGLXSA-N 2-hydroxy-N-[(E)-3-hydroxy-1-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)\C=C\CCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZXWQZGROTQMXME-KMPXOGLXSA-N 0.000 description 1
- 102100013894 BCL2 Human genes 0.000 description 1
- 108060000885 BCL2 Proteins 0.000 description 1
- 101700024247 BCL6 Proteins 0.000 description 1
- 102100011377 BCL6 Human genes 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 108091006011 G proteins Proteins 0.000 description 1
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 1
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862757755P | 2018-11-08 | 2018-11-08 | |
| US62/757,755 | 2018-11-08 | ||
| US201962826928P | 2019-03-29 | 2019-03-29 | |
| US62/826,928 | 2019-03-29 | ||
| PCT/US2019/060367 WO2020097403A1 (en) | 2018-11-08 | 2019-11-07 | Methods and combinations for treatment and t cell modulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512971A JP2022512971A (ja) | 2022-02-07 |
| JPWO2020097403A5 true JPWO2020097403A5 (ko) | 2022-11-14 |
Family
ID=69187891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525078A Pending JP2022512971A (ja) | 2018-11-08 | 2019-11-07 | 処置およびｔ細胞調節のための方法および併用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220008477A1 (ko) |
| EP (1) | EP3876958A1 (ko) |
| JP (1) | JP2022512971A (ko) |
| KR (1) | KR20210111247A (ko) |
| CN (1) | CN113573719A (ko) |
| AU (1) | AU2019377854A1 (ko) |
| BR (1) | BR112021008930A2 (ko) |
| CA (1) | CA3117978A1 (ko) |
| IL (1) | IL282886A (ko) |
| MX (1) | MX2021005366A (ko) |
| SG (1) | SG11202104411VA (ko) |
| WO (1) | WO2020097403A1 (ko) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス，インク． | メソテリン結合タンパク質 |
| EA202090739A1 (ru) | 2017-10-13 | 2020-09-07 | Харпун Терапьютикс, Инк. | Белки, связывающие антиген созревания в-клеток |
| CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| EP4054623A1 (en) * | 2019-11-07 | 2022-09-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione |
| AU2021263765A1 (en) * | 2020-04-28 | 2022-12-01 | Juno Therapeutics, Inc. | Combination of BCMA-directed T cell therapy and an immunomodulatory compound |
| PE20230494A1 (es) | 2020-05-08 | 2023-03-23 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas |
| US20220193134A1 (en) * | 2020-12-23 | 2022-06-23 | Crispr Therapeutics Ag | Co-use of lenalidomide with car-t cells |
| WO2022137186A1 (en) * | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
| MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
| EP4308927A1 (en) * | 2021-03-17 | 2024-01-24 | Mayo Foundation for Medical Education and Research | Methods and materials for identifying myeloma stage and drug sensitivity and treating myeloma |
| AU2022252220A1 (en) * | 2021-03-29 | 2023-10-12 | Juno Therapeutics, Inc. | Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma |
| US20240207310A1 (en) * | 2021-04-16 | 2024-06-27 | Celgene Corporation | Combination therapies with bcma-directed t cell therapy |
| EP4331678A1 (en) * | 2021-04-27 | 2024-03-06 | Oricell Therapeutics Co., Ltd. | Bcma-targeting chimeric antigen receptor and use thereof |
| WO2022256498A1 (en) * | 2021-06-03 | 2022-12-08 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| EP4412713A1 (en) * | 2021-10-05 | 2024-08-14 | GlaxoSmithKline Intellectual Property Development Ltd | Combination therapies for treating cancer |
| CN116338187B (zh) * | 2023-05-12 | 2023-10-03 | 中国人民解放军军事科学院军事医学研究院 | Wtap蛋白作为急性电离辐射损伤标志物的应用 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| EP0452342B1 (en) | 1988-12-28 | 1994-11-30 | MILTENYI, Stefan | Methods and materials for high gradient magnetic separation of biological materials |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| ES2339425T3 (es) | 1996-07-24 | 2010-05-20 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-il)-ftalimidas y -1-oxoisoindolinas sustituidas y procedimiento para reducir los niveles de tnf-alfa. |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| JP2001519143A (ja) | 1997-10-02 | 2001-10-23 | スノル・モレキュラー・コーポレーション | 可溶性の一本鎖ｔ細胞レセプタータンパク質 |
| TR200101501T2 (tr) | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı. |
| SK17332000A3 (sk) | 1998-05-19 | 2001-06-11 | Avidex Limited | Preskladaný rekombinantný t bunkový receptor-tcr, sekvencie nukleových kyselín, ktoré kódujú rekombinantné tcr reťazce rekombinantného tcr, a spôsob jeho výroby |
| JP2002524081A (ja) | 1998-09-04 | 2002-08-06 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 前立腺−特異的膜抗原に特異的な融合受容体およびその使用 |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| RU2001121987A (ru) | 1999-03-18 | 2004-02-27 | Селджин Корпорейшн (Us) | Замещенные 1-оксо- и 1,3-диоксоизоиндолины и их применение в фармацевтических композициях для снижения уровней воспалительных цитокинов |
| AU2001265346A1 (en) | 2000-06-02 | 2001-12-17 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| CA2439410C (en) | 2001-02-27 | 2011-09-06 | William D. Figg | Analogs of thalidomide as potential angiogenesis inhibitors |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| NZ531208A (en) | 2001-08-31 | 2005-08-26 | Avidex Ltd | Multivalent soluble T cell receptor (TCR) complexes |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2004033685A1 (en) | 2002-10-09 | 2004-04-22 | Avidex Ltd | Single chain recombinant t cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
| US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| EP2856876B1 (en) | 2007-03-30 | 2018-01-31 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US7615883B2 (en) | 2007-06-06 | 2009-11-10 | Meheen H Joe | Wind driven venturi turbine |
| JP5456689B2 (ja) | 2007-12-07 | 2014-04-02 | ミルテンイ バイオテック ゲーエムベーハー | 試料を少なくとも２つの成分に分離する遠心分離機 |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| WO2010025177A1 (en) | 2008-08-26 | 2010-03-04 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| LT2406284T (lt) | 2009-03-10 | 2016-10-10 | Biogen Ma Inc. | Antikūnai prieš b ląstelių subrendimo antigenus |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| PT2496698T (pt) | 2009-11-03 | 2019-04-18 | Hope City | Recetor de fator de crescimento epidermal truncado (egfrt) para seleção de células t transduzidas |
| ES2730763T3 (es) | 2010-02-11 | 2019-11-12 | Celgene Corp | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos |
| SG190997A1 (en) | 2010-12-09 | 2013-07-31 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| CN104080797A (zh) | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
| AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| CN104379179A (zh) | 2012-04-11 | 2015-02-25 | 美国卫生和人力服务部 | 靶向b-细胞成熟抗原的嵌合抗原受体 |
| SG11201407175RA (en) | 2012-05-03 | 2014-12-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
| CA2878954C (en) | 2012-08-09 | 2020-12-08 | Benjamin M. Cohen | Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same |
| SG11201501259QA (en) | 2012-08-20 | 2015-03-30 | Hutchinson Fred Cancer Res | Method and compositions for cellular immunotherapy |
| RU2020124583A (ru) | 2012-10-02 | 2020-08-03 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| DE112012007250T5 (de) | 2012-12-20 | 2015-10-08 | Mitsubishi Electric Corp. | Fahrzeuginterne Vorrichtung und Programm |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| CA3206268A1 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| CA2984484C (en) | 2014-05-02 | 2024-01-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| US20170226216A1 (en) | 2014-07-24 | 2017-08-10 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| BR112017005766B1 (pt) | 2014-09-22 | 2022-10-25 | Sacmi Cooperativa Meccanici Imola Societa' Cooperativa | Linha de produção para a fabricação de produtos, de forma sucessiva e método para a produção de produtos individuais, de forma sucessiva, em ciclo contínuo, em uma linha de produção |
| SG11201704548PA (en) | 2014-12-05 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Antibodies targeting b-cell maturation antigen and methods of use |
| CN107208047B (zh) | 2014-12-05 | 2021-09-21 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| ES2895640T3 (es) | 2014-12-12 | 2022-02-22 | 2Seventy Bio Inc | Receptores de antígenos quiméricos de BCMA |
| US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| EA201891289A1 (ru) | 2015-12-02 | 2018-11-30 | Селджин Корпорейшн | Циклическая терапия с применением 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона |
| EA201891965A1 (ru) | 2016-04-01 | 2019-04-30 | Кайт Фарма, Инк. | Химерные рецепторы антигенов и т-клеточные рецепторы и способы их применения |
| MX2019001184A (es) | 2016-07-29 | 2019-09-26 | Juno Therapeutics Inc | Anticuerpos anti-idiotípicos y métodos relacionados. |
| JP7278961B2 (ja) * | 2017-03-31 | 2023-05-22 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| FI3618842T3 (fi) * | 2017-05-01 | 2023-12-15 | Juno Therapeutics Inc | Soluterapian ja immunomodulatorisen yhdisteen yhdistelmä |
| WO2018223101A1 (en) * | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| WO2019109053A1 (en) * | 2017-12-01 | 2019-06-06 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
-
2019
- 2019-11-07 KR KR1020217017475A patent/KR20210111247A/ko active Search and Examination
- 2019-11-07 BR BR112021008930A patent/BR112021008930A2/pt unknown
- 2019-11-07 JP JP2021525078A patent/JP2022512971A/ja active Pending
- 2019-11-07 EP EP19842432.7A patent/EP3876958A1/en active Pending
- 2019-11-07 SG SG11202104411VA patent/SG11202104411VA/en unknown
- 2019-11-07 WO PCT/US2019/060367 patent/WO2020097403A1/en unknown
- 2019-11-07 AU AU2019377854A patent/AU2019377854A1/en active Pending
- 2019-11-07 US US17/292,363 patent/US20220008477A1/en active Pending
- 2019-11-07 CN CN201980088003.6A patent/CN113573719A/zh active Pending
- 2019-11-07 MX MX2021005366A patent/MX2021005366A/es unknown
- 2019-11-07 CA CA3117978A patent/CA3117978A1/en active Pending
-
2021
- 2021-05-03 IL IL282886A patent/IL282886A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020097403A5 (ko) | ||
| CN110475571B (zh) | 细胞免疫疗法前细胞毒性预调理的替代 | |
| JP2020518591A5 (ko) | ||
| Van De Donk et al. | Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma | |
| US20210145977A1 (en) | Methods and pharmaceutical composition for the treatment of cancer | |
| US20200038443A1 (en) | Multi-function and multi-targeting car system and methods for use thereof | |
| JP2020511462A5 (ko) | ||
| JP2019536460A5 (ko) | ||
| KR20230156808A (ko) | Car-t 세포의 조절 방법 | |
| WO2019114762A1 (zh) | 免疫效应细胞和辐射联用治疗肿瘤 | |
| JP2019532997A5 (ko) | ||
| Jung et al. | Immunotherapy for the treatment of multiple myeloma | |
| WO2018195348A9 (en) | Compositions and methods for treating cancer | |
| Weiner et al. | Antibodies and cancer therapy: versatile platforms for cancer immunotherapy | |
| JP2021500878A (ja) | 免疫療法のためのｔ細胞受容体 | |
| JP2024507283A (ja) | 抗腫瘍薬を調製するための免疫療法薬と併用でのｐｐａｒ－デルタ阻害剤の使用 | |
| WO2019114751A1 (zh) | 免疫效应细胞和辐射联用治疗肿瘤 | |
| TW202345908A (zh) | 用於治療ｔｒｏｐ－２表現性癌症之組合療法 | |
| Lu et al. | Multiple myeloma: signaling pathways and targeted therapy | |
| Vinay et al. | Harnessing immune checkpoints for cancer therapy | |
| JP2020533380A (ja) | 癌の組合せ治療 | |
| EP4323406A1 (en) | Co-inhibition of cd47/sirp? binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer | |
| JPWO2020252218A5 (ko) | ||
| CN113316449A (zh) | 胍那苄作为免疫疗法的佐剂 | |
| WO2019241536A1 (en) | Oxabicycloheptanes for enhancing car t cell function |